Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023.
Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023.
Windlas Biotech receives GMP certification for its new state-of-the-art injectable facility
10 - Jan - 2025 12:00 | 102 days ago
Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.
Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023.
Windlas Biotech receives GMP certification for its new state-of-the-art injectable facility
10 - Jan - 2025 12:00 | 102 days ago
Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.
Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023.
Windlas Biotech consolidated net profit rises 3.18% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Windlas Biotech rose 3.18% to Rs 15.58 crore in the quarter ended December 2024 as against Rs 15.10 crore during the previous quarter ended December 2023. Sales rose 20.23% to Rs 195.02 crore in the quarter ended December 2024 as against Rs 162.21 crore during the previous quarter ended December 2023.
Windlas Biotech receives GMP certification for its new state-of-the-art injectable facility
10 - Jan - 2025 12:00 | 102 days ago
Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines.